Clinical trials: Survival , Tumor
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of Avastin plus Herceptin/docetaxel, versus Herceptin/docetaxel alone, in patients with HER2 positive locally recurrent or metastatic breast cancer who have not received prior…
- Trial name
- NCT00391092
- Testing
- bevacizumab [Avastin], Docetaxel, Herceptin
- Where
- 89 sites in Argentina, Australia and 14 more
- Volunteers
- 424 people
- Sponsor
- Hoffmann-La Roche
Liver Cancer
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.
This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer.
- Trial name
- NCT00605722
- Testing
- bevacizumab (Avastin), erlotinib (Tarceva)
- Where
- 6 sites in Philippines, South Korea and 1 more
- Volunteers
- 51 people
- Sponsor
- Hoffmann-La Roche
Prostatic Neoplasms
Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
Primary Objective: Describe real-life survival of CRPC patients who received first-line docetaxel and have disease progression Secondary Objective: Describe treatment patterns Describe the characteristics and outcomes of patients…
- Trial name
- PORTREAT (NCT01076751)
- Where
- 5 sites in United States, France and 3 more
- Volunteers
- 82 people
- Sponsor
- Sanofi
Diffuse Large B-cell Lymphoma
Real-World HRU and Costs in DLBCL Pts With Tisa-cel and Axi-cel, a Medicare Study.
This was a retrospective non-interventional cohort study design using the Centers for Medicare and Medicaid Services (CMS) 100% Medicare data (2015Q1-2020Q4).
- Trial name
- NCT06271369
- Where
- United States
- Volunteers
- 613 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Brain Tumor, Primary Brain Tumor
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical.
- Conditions
- Metastatic Brain Tumor, Primary Brain Tumor, Epileptic/Seizure Foci, Movement Disorders
- Trial name
- LAANTERN (NCT02392078)
- Testing
- NeuroBlate System
- Where
- 26 sites in United States
- Volunteers
- 1,153 people
- Sponsor
- Monteris Medical
Multiple Myeloma Survival Outcome, Multiple Myeloma and Malignant Plasma Cell Neoplasms
Multiple Myeloma Extramedulary Disease Samples FFPE
This observational study aims to evaluate the feasibility of assembling a retrospective cohort of formalin-fixed paraffin-embedded (FFPE) tissue samples from patients with extramedullary multiple myeloma, together with their…
- Trial name
- MMExFFPE (NCT07354555)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- BIWAKO
Colorectal Cancer
A Study of Avastin (Bevacizumab) in Combination With Xelox and Tarceva in Patients With Metastatic Colorectal Cancer.
This study will evaluate the efficacy and safety of a first-line regimen of Avastin and Xelox (Xeloda + Eloxatin) followed by Avastin and Tarceva, in patients with metastatic colorectal cancer.
- Trial name
- NCT01135498
- Testing
- bevacizumab [Avastin], eloxatin, capecitabine [Xeloda]
- Where
- 12 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Pancreatic Cancer, Borderline Resectable Pancreatic Cancer
Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally Advanced Pancreatic Cancer
The purpose of this Interventional clinical trial is to evaluate safety and efficacy of 'IMD10 (focused ultrasound)' in the treatment of borderline resectable pancreatic cancer or locally advanced pancreatic cancer.
- Conditions
- Pancreatic Cancer, Borderline Resectable Pancreatic Cancer, Locally Advanced Pancreatic Cancer
- Trial name
- SonoPANIII (NCT07325214)
- Testing
- IMD10, chemotherapy regimen [irinotecan hydrochloride, oxaliplatin, fluorouracil (5-FU) and leucovorin]
- Where
- 5 sites in United States, South Korea
- Volunteers
- 360 people
- Sponsor
- IMGT Co., Ltd.
Glioblastoma Multiforme
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
The purpose of the PRECISE trial is to determine whether overall survival duration, safety, and quality of life are improved for patients treated with IL13-PE38QQR compared to patients treated with GLIADEL® Wafer following…
- Trial name
- NCT00076986
- Testing
- IL13-PE38QQR, surgery and catheter placement (2 procedures), prolifespan 20 with carmustine implant (GLIADEL® Wafer)
- Where
- 60 sites in United States, Canada and 4 more
- Volunteers
- 300 people
- Sponsor
- INSYS Therapeutics Inc
Acute Myeloid Leukemia (AML)
A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)
The purpose of this study was to confirm the preliminary evidence from early clinical trials that midostaurin may provide clinical benefit not only to AML patients with the FLT3-mutations but also in FLT3-MN (SR<0.05) AML (FLT3…
- Trial name
- NCT03512197
- Testing
- Midostaurin, Chemotherapy
- Where
- 133 sites in United States, Argentina and 18 more
- Volunteers
- 511 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer Metastatic
RWE on Patients With mPDAC Long-term Survival After Treatment With Liposomal Irinotecan
The objective is to describe mPDAC patients still alive one year after the first cycle of nal-IRI
- Trial name
- NALLONG (NCT06155136)
- Where
- Germany
- Volunteers
- 163 people
- Sponsor
- Servier Affaires Médicales
Non-Small Cell Lung Cancer, Advanced Solid Tumours
Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours
A Phase I, open-label, multicentre, dose-escalation study to investigate the safety, pharmacokinetics and maximum tolerated dose (MTD) of AZD4785 in patients with advanced solid tumours where KRAS may be an important driver of…
- Trial name
- NCT03101839
- Testing
- AZD4785
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- AstraZeneca
Breast Neoplasms, Neoplasms, Hormone-Dependent
Treatment and Survival Continuation Study of Atamestane Plus Toremifene vs Letrozole in Advanced Breast Cancer
Protocol 777-CLP-32 is the treatment and survival continuation protocol of Biomed 777-CLP-29, and will continue to compare combined hormonal therapy using the experimental aromatase inhibitor (AI) atamestane combined with the…
- Trial name
- NCT00267553
- Testing
- Atamestane, toremifene, letrozole
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 200 people
- Sponsor
- Intarcia Therapeutics
Pancreatic Ductal Adenocarcinoma (PDAC)
Expanded Access to PCNAT-01 for Patients With Resected Pancreatic Ductal Adenocarcinoma Following Surgical Resection and Adjuvant Therapy
This expanded access program provides a potential pathway for eligible patients with resected pancreatic ductal adenocarcinoma (PDAC) to receive PCNAT-01, an investigational, personalized tumor neoantigen peptide vaccine, outside…
- Trial name
- NCT07612930
- Testing
- PCNAT-01
- Sponsor
- Anda Biopharmaceutical Development (Shenzhen) Co., Ltd.
ER/PR(+), Her2(-) Breast Cancer
Clinical Outcome Of Hormonal Receptor Positive, Her-2 Negative Breast Cancer In Taiwan
Breast cancer is the most common cancer in Taiwanese women. Most of them were diagnosed in relatively early stages. Only 700 metastatic breast cancer were registered in Official Cancer Registration 2012, while more than11,305…
- Trial name
- NCT02924584
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer
Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.
- Trial name
- NCT00033904
- Testing
- autologous human tumor-derived HSPPC-96
- Where
- 76 sites in United States, Austria and 9 more
- Volunteers
- 650 people
- Sponsor
- Agenus Inc.
Non-small Cell Lung Cancer
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.
- Trial name
- NCT01000740
- Testing
- EGFR Mutation Test, Ki-67 protein expression
- Where
- 9 sites in China
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Gastrointestinal Stromal Tumor
Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)
This study will assess time-to-disease progression in patients with advanced gastrointestinal stromal tumor (GIST) previously treated with imatinib ≥600 mg.
- Trial name
- NCT01110668
- Testing
- Nilotinib
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Renal Cell Carcinoma
A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival
This is a retrospective, non-interventional study which looks at the cohort of Renal Cell Carcinoma patients in a real life clinical setting and analyses into factors why these patients have been surviving for as long as 3-5…
- Trial name
- NCT01917214
- Testing
- Sutent: Observational Study
- Volunteers
- 212 people
- Sponsor
- Pfizer
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free…
- Trial name
- BOLERO-3 (NCT01007942)
- Testing
- everolimus, vinorelbine, trastuzumab
- Where
- 161 sites in United States, Argentina and 19 more
- Volunteers
- 569 people
- Sponsor
- Novartis Pharmaceuticals